CDC Vaccine Panel Postpones Vote on Delaying Newborn Hepatitis B Shot

The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) has postponed a vote on whether to delay the first dose of the hepatitis B vaccine for newborns. The current recommendation is to administer this vaccine within 24 hours of birth. The proposed change would have delayed the initial dose until at least one month of age for infants born to mothers who tested negative for hepatitis B.

During the meeting, several ACIP members expressed concerns about the potential risks of delaying the vaccine. Dr. Cody Meissner, a committee member, stated, "We will increase the risk of harm based on no evidence of benefit, because there will be fewer children who will get the full hepatitis B vaccine series."

The hepatitis B vaccine has been recommended for newborns in the United States since 1991. Following its implementation, hepatitis B infections in infants dropped from an average of 18,000 per year to around 20 reported cases annually.

In a related decision, the ACIP voted to recommend that children under four receive the measles, mumps, rubella, and varicella (MMRV) vaccines separately, rather than as a combined MMRV vaccine. This recommendation aligns with the Vaccines for Children program, which provides low-cost or free vaccines to eligible children.

The ACIP's recommendations are not final until approved by the CDC Director. The Department of Health and Human Services stated that it "will examine all insurance coverage implications following today's ACIP recommendation, prior to a final decision on adoption by the Acting Director."

The committee is tentatively scheduled to meet again in October to revisit these topics.